Vycor Medical, Inc.
Vycor Medical, Inc. (VYCO) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Vycor Medical, Inc. (VYCO), covering cash flow, earnings, and balance sheets.
Vycor Medical, Inc. (VYCO) Income Statement & Financial Overview
Review Vycor Medical, Inc. VYCO income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $436378.00 | $455226.00 | $390852.00 | $406278.00 |
| Cost of Revenue | $77844.00 | $57844.00 | $36796.00 | $35163.00 |
| Gross Profit | $358534.00 | $412262.00 | $354056.00 | $371115.00 |
| Gross Profit Ratio | $0.82 | $0.91 | $0.91 | $0.91 |
| R&D Expenses | $5762.00 | $6637.00 | $6425.00 | $2263.00 |
| SG&A Expenses | $350698.00 | $356521.00 | $367886.00 | $337793.00 |
| Operating Expenses | $356460.00 | $378038.00 | $374311.00 | $340056.00 |
| Total Costs & Expenses | $434304.00 | $435882.00 | $425987.00 | $390100.00 |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | -$12570.00 | $26051.00 | $25990.00 | $26168.00 |
| Depreciation & Amortization | $14880.00 | $16869.00 | $15740.00 | $15681.00 |
| EBITDA | -$36204.00 | $36233.00 | -$18035.00 | $31859.00 |
| EBITDA Ratio | -$0.08 | $0.08 | -$0.05 | $0.08 |
| Operating Income | -$38514.00 | $19344.00 | -$35135.00 | $16178.00 |
| Operating Income Ratio | -$0.09 | $0.04 | -$0.09 | $0.04 |
| Other Income/Expenses (Net) | $0.00 | -$26029.00 | -$24635.00 | -$26167.00 |
| Income Before Tax | -$38514.00 | -$6685.00 | -$59770.00 | -$9989.00 |
| Income Before Tax Ratio | -$0.09 | -$0.01 | -$0.15 | -$0.02 |
| Income Tax Expense | $49.00 | $148.00 | $0.00 | $0.00 |
| Net Income | -$38563.00 | -$6737.00 | -$59817.00 | -$10038.00 |
| Net Income Ratio | -$0.09 | -$0.01 | -$0.15 | -$0.02 |
| EPS | -$0.001 | $0.005 | -$0.007 | -$0.00 |
| Diluted EPS | -$0.001 | $0.005 | -$0.007 | -$0.00 |
| Weighted Avg Shares Outstanding | $33.37M | $32.88M | $32.90M | $32.63M |
| Weighted Avg Shares Outstanding (Diluted) | $33.37M | $32.88M | $32.90M | $32.63M |
The company's financials show resilient growth, with revenue advancing from $406278.00 in Q2 2024 to $436378.00 in Q1 2025. Gross profit remained healthy with margins at 82% in Q1 2025 compared to 91% in Q2 2024. Operating income hit -$38514.00 last quarter, sustaining a consistent -9% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$36204.00. Net income dropped to -$38563.00, while earnings per share reached -$0.001. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan